

May 23, 2019

The National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E) Mumbai - 400051 The Bombay Stock Exchange Limited Corporate Relationship Department Phiroze Jeejeeboy Towers Dalal Street, Mumbai – 400001

# Subject: Disclosure of information under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Regulations"), please find attached herewith Corporate Presentation of the Company for Financial Year 2018-19, which the Company proposes to share with analysts/investors.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited nLa Rajat Kalra

Company Secretary and Legal Head

Encl: As above

E Dr Lal PathLabs

# **Dr. Lal PathLabs Limited**



# **Corporate Presentation**

May 2019

### Disclaimer

By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the "Company") for use in presentations by the Company at analyst and investor meetings and does not constitute a recommendation regarding the securities of the Company. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. Neither the Company nor any of its advisors or representatives is under any obligation to update or keep current the information contained herein. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not unduly rely on these forward looking statements. The Company, its advisors and representatives assume no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus under the (Indian) Companies Act, 2013 and will not be registered with any registrar of companies. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities for sale in the India. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States securities laws. This presentation and the information contained herein is being furnished to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the U.S., Canada, Australia, Japan or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the United States or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By reviewing this presentation, you are deemed to have represented and agreed that you and any person you represent are either (a) a qualified institutional buyer (within the meaning of Regulation 144A under the Securities Act) or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or benefit of a U.S. person.





1	Company overview
2	Investment highlights
3	Q4 & FY19 highlights & financial performance
4	LPL strategy for future growth
5	Annexures

DISCLAIMER: This presentation may contain 'forward-looking' statements at places. The Company's business operations remain subject to undetermined contingencies and risks. Dr. Lal PathLabs Limited would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.





### **Company Overview**

- Our Evolution
- Dr. Lal PathLabs at a glance
- Experienced Management team

### **Our Evolution**

**1949 – 2005** 

Foundation

## 2005 - 2010

Building capabilities for scale up

# <u> 2010 – 2019</u>

Strong position in North India, building network in other geographies

- **1949:** Founded by Dr. Major S. K. Lal
- 1995: Company incorporated as Dr. Lal PathLabs Private Ltd.
- 2000: Three clinical labs receive NABL<sup>1</sup> accreditation
- 2001: Received ISO 9001:2008 certification
- 2002: Received 'International Accreditation' from CAP<sup>2</sup>

- 2005: onwards: Investment by WestBridge Capital
- 2008: Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited
- **2010:** National Reference Lab set up in Delhi

- Investment by TA Associates
- Clinical laboratories expansion
  in North region
- Growing the business in East region
- Entry into the South and West regions
- Multiple acquisitions to scale network
- Successful IPO listing in Dec 2015
- New Regional Reference Lab in Kolkata started in 2018

#### 1. NABL: National Accreditation Board for Calibration and Testing Laboratories.

2. CAP: College of American Pathologists.



### Dr. Lal PathLabs at a glance

# Established consumer healthcare brand in diagnostic services

**Pan-India integrated coverage** with **200** clinical labs (including National Reference Lab<sup>1</sup> at Delhi and Regional Ref Lab at Kolkata), **2,569** Patient Service Centers (PSCs) and **6,426** Pick-up Points (PUPs)<sup>2</sup>

Catalogue of **478** test panels, **2,425** pathology tests and **1,772** radiology and cardiology tests<sup>2a</sup>

Collected and processed **~10.6 mn** samples from **~4.3 mn** patients in Q4 FY19; **~41.8 mn** samples from **~17.6 mn** patients in FY19; **~34.7 mn** samples from **~15.2 mn** patients in FY18;


**Customers** include individual patients, corporates and institutions, healthcare providers as well as hospital and clinical labs (lab management)

**~4,405** employees including full time consultants, pathologists, phlebotomists and radiologists<sup>2</sup>

FY19: Revenue: INR 12,034 mn; EBITDA: INR 3,132 mn<sup>3</sup> (Margin: 26%); PAT: INR 2,005 mn (Margin: 16.7%); FY18: Revenue: INR 10,569 mn; EBITDA : INR 2,783 mn (Margin: 26.3%); PAT: INR 1,718 mn (Margin: 16.3%)

1. Total area of 7,253 square meters 2. As on March 31, 2019. 2a As on Dec 31, 2018 3. Normalised EBITDA excl RSU and stock based comp. & CSR Cost

#### Test Menu



#### Accreditations



### **Experienced Management team**



(Hony.) Brig. Dr. Arvind Lal

Chairman and Managing Director



Dr. Om Manchanda Whole-time Director and Chief

Executive Officer

CEO India Business



Dr. Vandana Lal *Whole-time Director* 



Ved Prakash Goel

Chief Financial Officer



Bharath Uppiliappan



Shankha Banerjee

Chief Growth Officer



Munender Soperna

Chief Information Officer



Dr. Neelum Tripathi

National Director Lab Operations



Manoj Garg

Chief Human Resources Officer



Rajat Kalra

Company Secretary and Compliance Officer



#### Manoj Sahay

Chief Marketing and Strategy Officer





## **Investment Highlights**

### **Investment Highlights**

# 1

Well-positioned in one of the fastest-growing segments of the Indian healthcare industry

Established consumer healthcare brand in diagnostic services

# 3

Scalable model integrated through centralized IT platform allows for network expansion


# 4

Attractive operating metrics and multiple levers in place to drive next phase of growth

Robust financial performance and return on invested capital

5





Source: CRISIL Report titled "Assessment of Diagnostics Industry in India".

1. Financial Year ending March 31<sup>st</sup>.

2. Source: Report of the Insurance Regulatory and Development Authority ("IRDA")


3. Source: World Health Organization Global Health Expenditure database, October 2017, 4. IMF

Indian Healthcare Services is a large growth

# 🚆 Dr Lal PathLabs

INR 596 bn Diagnostic Services industry expected to grow to INR 802 bn by FY20

### **Diagnostic Services Industry Size**



Screening, early detection, and monitoring reduce downstream costs

Source: Frost & Sullivan Research

# **Growth Drivers**

**1** *Increase in evidence-based treatments* 

2 Demand for lifestyle diseasesrelated services to grow

3


Focus on preventive diseases and wellness



ſ

**Diagnostic Services industry remains highly fragmented** 

### **Highly Fragmented Industry**



Source: CRISIL Report titled "Assessment of Diagnostics Industry in India".

12

ſ




#### **Pillars of a Strong Brand Nationwide Network** Accreditations **Fast Turnaround Time** Accreditations from CAP, • Coverage in metros, Tier 1 24x7 access including online NABL and ISO and Tier 2 cities access and home collection Centrally administered • Wide reach through PSCs Dedicated logistics team surveillance programs and PUPs Medico Marketing Doctor Online Call Query Handling Registration Centre Offline • · · Online Lab Customer **Report Delivery** Sample Collection Offline Home **Retail Marketing Digital Marketing** Walk-in customers account for • • Single brand pulls patients • Diverse and large customer pool highest share of revenues



### Scalable Model integrated through centralized IT platform allows for network expansion

### **Hub and Spoke Model**





- Centralized diagnostic testing provides greater economies of scale
- PSCs and PUPs facilitate penetration within region and expand reach

1. Includes National Reference Laboratory.

### **Network Expansion**

#### No. of Clinical Laboratories








2,569

Scalable Model integrated through centralized IT platform allows for network expansion



### Integrated National Network...





• Bi-directional interface; tracks specimen collection, shipping and testing in real time

• Payables, receivables, inventory, ledgers etc.


Scalability and connectivity – web-based

• Assigns unique ID / barcode for each sample

- Improve diagnostic services via data analyses
- Demand for tests are analyzed using past data




### LPL's scalable business model provides strategic advantage for expansion and consolidation



16

### **Attractive operating metrics**





2 Dr Lal PathLabs

# Multiple levers in place to drive next phase of growth



18

### Expand presence in existing markets

- Cluster and focused geography approach
  - Deepen presence in North India by developing additional reference labs
  - Scale up in East India by developing ecosystems via Kolkata reference lab
  - Targeted expansion in South and West India (focused city approach)

Expand through strategic acquisitions and partnerships

- M&A provides growth kicker
- Leverage prior track record
  - Completed several acquisitions since 2008
- Acquisition opportunities in select new geographies

#### Focus on hospitalbased clinical labs

- Increase existing tie-ups
- Leverage scale and efficiency
- Provide lab management and specialized lab testing services to polyclinics


Increase breadth of diagnostic healthcare testing and services platform


Continuous focus on providing quality healthcare services




North In	dia	ast India		South and West India	
Focus on retail network and home collection	Commitment to <b>quality</b> <b>and reliability</b> of services	Online report data analytic		<b>Preventive hea</b> <b>screening</b> and a / lifestyle disease services. Bundlin	chronic e manageme
Focus on hospital lab management	Provide both <b>lab</b> management and specialized lab testin polyclinics	ig to	in hospital la	<b>xisting tie-ups</b> ab management – <b>cale and efficiency</b>	
Focus on corporate	Marketing to HR departments and othe	ar i	<b>althcare pa</b> e oss test types	_	


### **Robust financial performance**





#### **EBITDA<sup>1</sup>,PAT and Return on Net Worth** (INR mn / %)





- Growth driven primarily by increasing patient volumes and samples
- Increase in operating margin due to economies of scale


<sup>1.</sup> During FY14, LPL had reassessed the ESOP scheme as cash settled basis as against equity settled basis treated in earlier years' financial statements. As a result, LPL accounted for additional compensation cost of INR 8.9 mn in FY16. ESOP/RSU/ESPS charge of INR 86.1 mn in FY17 is also excluded. FY16 & FY17 also excluded the impact of CSR Expense of INR 3.8 mn and INR 18.7 mn respectively for ease of comparison.



### **Robust financial performance (Cont'd)**




Fixed Asset Turnover<sup>1</sup>



### **Cash and Cash Equivalents**

(INR mn)




- Self funded growth on account of strong cash flow generation
- Attractive fixed asset turnover ratio given asset-light model
- Current net cash position and internal accruals expected to fund next phase of growth

1. Fixed Asset Turnover = Total Revenue / Net Fixed Assets as per IndAS





Q4 & FY19 Highlights & Financial Performance



### **Key Performance Highlights**

Consistent growth in patient volumes for Q4 at 12.5% driving revenue growth for the quarter

#### During Q4 FY19:

- Revenues gained 12.9% YoY to Rs 3,011 million
- Number of patients tested stood at 4.32 million in Q4
- Normalised EBITDA (after eliminating the impact of stock based remuneration and CSR) was at Rs 729 million
- PAT for Q4 stood at Rs 474 million which is a growth of 17.9% over Q4FY19

Cash, FDs and Liquid Investments at Rs. 7,077 million as at March 31, 2019 from Rs. 6,537 million as at December 31, 2018, an increase of Rs. 540 million in Q4 FY19

Company continues to deliver volume growth through increased penetration, introduction of newer tests and inorganic growth while retaining EBITDA margins


- Acquisition of a pathology laboratory in Maharashtra in April'19 further strengthening our presence in the Central and Western region
- Normalised EBITDA margins for FY'19 at 26 % as against 26.3% in FY'18
- Recommend Final Dividend of Rs 3.50 share in addition to Rs 2.50 paid as Interim Dividend

Note: Financial results of the Company are best monitored on a year to date basis, as there is a certain level of seasonality in business and specific quarter performance may be influenced by certain occurrences in that quarter. All figures in the presentation pertain to the consolidated results in Ind-AS format.

### **Financial Table**


Particulars (Rs. mn)	Q4 FY19	Q4 FY18	Growth %	FY19	FY18	Growth %
Revenue	3,011	2,668	<i>12.9%</i>	12,034	10,569	13.9%
Expenditure	2,349	2,028		9,098	7,929	
EBITDA	662	640	3.4%	2,936	2,640	11.2%
Adj for stock based comp. & CSR Cost	67	48		196	143	
Normalised operating EBITDA	729	688	6.0%	3,132	2,783	12.5%
Normalised Margins	24.2%	25.8%		26.0%	26.3%	
Other income incl interest	135	89		459	312	
РВТ	692	620	11.6%	3,006	2,613	15.0%
Margins	23.0%	23.2%		25.0%	24.7%	
ΡΑΤ	474	402	17.9%	2,005	1,718	16.7%
Margins	15.7%	15.1%		16.7%	16.3%	
EPS (Basic)	5.72	4.88	17.2%	24.19	20.85	16.0%
EPS (Diluted)	5.71	4.87	17.2%	24.15	20.82	16.0%

### **Financial Highlights**




Financial results of the Company are best monitored on a year to date basis, as there is a certain level of seasonality in business and specific quarter performance may be influenced by certain occurrences in that quarter

### **Financial Highlights**





## LPL Strategy for future growth






### Annexures

• Shareholding as of 31st March, 2019

### Shareholding as of 31st Mar, 2019



### **Contact us**

#### About Dr Lal PathLabs Limited (DLPL)

Dr Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services\* includes 478 test panels, 2,425 pathology tests and 1,772 radiology and cardiology tests.

As on March 31, 2019 DLPL's has 200 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 2,569 Patient Service Centers (PSCs) and 6,426 Pick-up Points (PUPs). In FY18 & FY19, DLPL collected and processed approximately 34.7 million samples and 41.8 million samples from approximately 15.2 million and 17.6 million patients, respectively.

#### Additional information on Dr Lal PathLabs Limited:

Corporate Identification No: L74899DL1995PLC065388 Website: <u>https://www.lalpathlabs.com</u>

\*As on 31 Dec 2018

#### For further information please contact:

Ved Goel / Rajat Kalra Dr. Lal PathLabs Limited Tel: +91 124 301 6500 Fax: +91 124 423 4468 E-mail: Ved.Goel@lalpathlabs.com /Rajat.Kalra@lalpathlabs.com

#### Siddharth Rangnekar / Nishid Solanki CDR India

Tel: +91 22 66451209 / 1221 Fax: +91 22 66451213 Email: siddharth@cdr-india.com / nishid@cdr-india.com